Compounded (503A/503B)Also: Copper Peptide, Glycyl-Histidyl-Lysine Copper

GHK-Cu Dosage Chart

Topical, subcutaneous, and oral protocols for the copper peptide GHK-Cu, with reconstitution math for the 50 mg and 100 mg vials.

Written by
Megan Williams
Editor-in-Chief
Reviewed by
Brian Williams
Co-founder & Research Editor
Last updated
April 25, 2026

Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.

GHK-Cu is a tripeptide that naturally complexes with copper. It has the longest research history of any peptide on this site — Pickart's original work dates to the 1970s — and is well-validated in topical cosmetic literature. Injectable use is more recent and protocol-driven by clinician practice rather than formal trials.

GHK-Cu at a Glance

Topical0.05–2% creams and serums, applied 1–2× daily
Subcutaneous injection1–2 mg/day for 4–6 week cycles
OralGenerally not used — poor bioavailability
Cycle length4–8 weeks injectable, 2–4 weeks off; topical can be continuous
FDA statusTopical formulations are sold as cosmetics. Injectable use is compounded and not FDA-approved.
Common usesSkin (collagen, fine lines, wound healing), hair (follicle support), tissue repair
Common vial size50 mg or 100 mg lyophilized powder

GHK-Cu Reconstitution Chart

How vial size, bacteriostatic water volume, and insulin-syringe units convert for GHK-Cu. Use this to translate a prescribed mcg or mg dose into a syringe measurement.

Vial sizeBac waterConcentrationDose → insulin-syringe units (U-100)
50 mg5 mL10 mg/mL (1 mg per 0.1 mL)
  • 1 mg10 units
  • 2 mg20 units
100 mg5 mL20 mg/mL (2 mg per 0.1 mL)
  • 1 mg5 units
  • 2 mg10 units

GHK-Cu Dosing by Use Case

Commonly cited protocols vary by what GHK-Cu is being used for. The table below summarizes typical ranges reported in clinical practice and published literature.

Use caseTypical doseFrequencyCycle lengthNotes
Skin / anti-aging (topical)0.05–2% concentration1–2× daily, applied to clean skinContinuousCosmetic literature is the most evidence-supported use case.
Hair support (topical scalp serum)0.05–0.1% concentrationDaily scalp applicationContinuous, evaluate at 12+ weeksOften layered with minoxidil; not a replacement for it.
Tissue repair / systemic recovery (subQ)1–2 mgOnce daily4–6 weeksRotate injection sites; can sting at injection site.

Stacking GHK-Cu

GHK-Cu is sometimes layered with BPC-157 and TB-500 for systemic tissue recovery. Topical GHK-Cu is commonly used alongside other topical actives (retinoids, vitamin C) but at separate times of day to preserve stability.

Safety profile

GHK-Cu has a long topical safety record and a generally clean profile. Injectable use carries theoretical copper-overload concerns at high doses.

  • Topical use is well-tolerated; rare reports of local irritation or contact dermatitis.
  • Injection sting at the site is the most common acute complaint — usually transient.
  • Theoretical: chronic high-dose injectable use could contribute to copper overload, especially in patients with Wilson's disease or impaired biliary copper excretion.
  • Not FDA-approved for injection. Topical cosmetic formulations are widely available.
Do not use if
  • Wilson's disease or hereditary copper-handling disorders
  • Active malignancy (relative contraindication for injectable use)
  • Pregnancy or breastfeeding (limited safety data for injectable use)

GHK-Cu Dosing FAQ

For skin and hair use cases, topical is the better-validated route — most published evidence comes from cosmetic studies. For systemic tissue repair, injectable is the only effective route because oral GHK-Cu has poor bioavailability.

We don't recommend it. Topical formulations require specific carrier ingredients to penetrate skin and remain stable; pharmaceutical-grade cosmetic formulations are widely available and avoid the sterility, stability, and concentration uncertainty of DIY mixing.

Topical skin changes are typically reported at 8–12 weeks of consistent use. Hair changes take 3–6 months. Injectable use targeting tissue repair is usually evaluated at the end of a 4–6 week cycle.

Sources

Related Dosage Charts

Want the full GHK-Cu guide?

Mechanism, clinical evidence, side effects, costs, and provider listings for GHK-Cu therapy.

See GHK-Cu guide

Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.